Spread of colistin resistant non-mucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients

Journal of Cystic Fibrosis

Volumn 7, Issue 5, 2008, Pages 391-397

  Johansen, Helle Krogh ^a,b   Moskowitz, Samuel M ^c   Ciofu, Oana ^b   Pressler, Tacjana ^a   Høiby, Niels ^a,b  

^a Department of Clinical Microbiology   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

Colistin resistance; Cystic fibrosis; Outbreak; P. aeruginosa

Indexed keywords

AZTREONAM; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN;

ADOLESCENT; ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL TRANSMISSION; BACTERIUM ISOLATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS INFECTION; CYSTIC FIBROSIS; DENMARK; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EPIDEMIC; ERADICATION THERAPY; FOLLOW UP; GENOTYPE; HOSPITAL ADMISSION; HUMAN; INFECTION CONTROL; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; OUTPATIENT DEPARTMENT; PATIENT CARE; PSEUDOMONAS AERUGINOSA; PULSED FIELD GEL ELECTROPHORESIS; RESPIRATORY TRACT INFECTION; TREATMENT DURATION;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; CHILD; COLISTIN; CYSTIC FIBROSIS; DENMARK; DISEASE OUTBREAKS; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; PATIENT ISOLATION; PROSPECTIVE STUDIES; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY FUNCTION TESTS;

EID: 51549106318     PISSN: 15691993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcf.2008.02.003     Document Type: Article

References (44)

1. Johansen H.K., and Høiby N. Seasonal onset of initial colonisation and chronic infection with Pseudomonas aeruginosa in patients with cystic fibrosis in Denmark. Thorax 47 (1992) 109-111
2. Høiby N., and Frederiksen B. Microbiology of cystic fibrosis. In: Hodson M.E., and Geddes D.M. (Eds). Cystic Fibrosis. 2nd edition (2000), Arnold, London 83-107
3. Høiby N., Frederiksen B., and Pressler T. Eradication of early Pseudomonas aeruginosa infection. J Cyst Fibros 4 Suppl 2 (2005) 49-54
4. Jensen T., Pedersen S.S., Garne S., Heilmann C., Høiby N., and Koch C. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother 19 (1987) 831-838
5. Frederiksen B., Koch C., and Høiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 23 (1997) 330-335
6. Littlewood J.M., Miller M.G., Ghoneim A.T., and Ramsden C.H. Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis. Lancet 8433 (1991) 865-866
7. Muhle S.A., and Tam J.P. Design of gram-negative selective antimicrobial peptides. Biochemistry 40 (2001) 5777-5785
8. Moskowitz S.M., Ernst R.K., and Miller S.I. PmrAB, a two-component regulatory system of Pseudomonas aeruginosa that modulates resistance to cationic antimicrobial peptides and addition of aminoarabinose to lipid A. J Bacteriol 186 (2004) 575-579
9. Trent M.S., Ribeiro A.A., Lin S., Cotter R.J., and Raetz C.R. An inner membrane enzyme in Salmonella and Escherichia coli that transfers 4-amino-4-deoxy-l-arabinose to lipid A: induction on polymyxin-resistant mutants and role of novel lipid-linked donor. J Biol Chem 276 (2001) 43122-43131
10. Landman D., Bratu S., Alam M., and Quale J. Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B. J Antimicrob Chemother 55 (2005) 954-957
11. Denton M., Kerr K., Mooney L., Keer V., Rajgopal A., Brownlee K., Arundel P., and Conway S. Transmission of colistin-resistant Pseudomonas aeruginosa between patients attending a pediatric cystic fibrosis center. Pediatr Pulmonol 344 (2002) 257-261
12. Lee T.W.R., Brownlee K.G., Denton M., Littlewood J.M., and Conway S.P. Reduction in prevalence of chronic Pseudomonas aeruginosa infection at a regional pediatric cystic fibrosis center. Pediatr Pulmonol 37 (2004) 104-110
13. Taccetti G., Campana S., Festini F., Mascherini M., and Döring G. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients. Eur Respir J 26 (2005) 458-461
14. Li J., Turnidge J., Milne R., Nation R.L., and Coulthard K. In vitro pharmacodynamic properties of colistin and colistin methanesulfate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob Agents Chemother 45 (2001) 881-885
15. Schülin T. In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany. J Antimicrob Chemother 49 (2002) 403-406
16. Hansen C.R., Pressler T., and Høiby N. Experience from 15 years use of inhaled colistin in treatment of P. aeruginosa in a CF-clinic. J Cyst Fibros 4 Suppl 1 (2005) S54
17. Johansen H.K., Nørregaard L., Gøtzsche P.C., Pressler T., Koch C., and Høiby N. Antibody response to Pseudomonas aeruginosa in cystic fibrosis patients: a marker of therapeutic success? A 30-year cohort study of survival in Danish CF patients after onset of chronic P. aeruginosa lung infection. Pediatr Pulmonol. 37 (2004) 427-432
18. Pedersen S.S., Jensen T., Høiby N., Koch C., and Flensborg E.W. Management of Pseudomonas aeruginosa lung infection in Danish cystic fibrosis patients. Acta Paediatr Scand 76 (1987) 955-961
19. Pedersen S.S., Koch C., Høiby N., and Rosendal K. An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis center. J Antimicrob Chemother 17 (1986) 505-516
20. Frederiksen B., Lanng S., Koch C., and Høiby N. Improved survival in the Danish center-treated cystic fibrosis patients: results of aggressive treatment. Pediatr Pulmonol 21 (1996) 153-158
21. Frederiksen B., Koch C., and Høiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr Pulmonol 23 (1997) 330-335
22. Jørgensen I.M., Johansen H.K., Frederiksen B., Hansen A., Høiby N., and Koch C. Pandoraea apista: an emerging pathogen in cystic fibrosis. An example of a local epidemic. Pediatr Pulmonol 36 (2003) 439-446
23. Valerius N.H., Koch C., and Høiby N. Prevention of chronic Pseudomonas aeruginosa colonization in cystic fibrosis by early treatment. Lancet 338 (1991) 725-726
24. Ciofu O., Jensen T., Pressler T., Johansen H.K., Koch C., and Høiby N. Meropenem in cystic fibrosis patients infected with resistant Pseudomonas aeruginosa or Burkholderia cepacia and with hypersensitivity to beta-lactam antibiotics. Clin Microbiol Infect 2 (1996) 91-98
25. Ojeniyi B., Frederiksen B., and Høiby N. Pseudomonas aeruginosa cross-infection among patients with cystic fibrosis during a winter camp. Pediatr Pulmonol 29 (2000) 177-181
26. Ojeniyi B., Høiby N., and Rosdahl V.T. Genome fingerprinting as a typing method used on polyagglutinable Pseudomonas aeruginosa isolates from cystic fibrosis patients. Acta Pathol Microbiol Immunol Scand 99 (1991) 492-498
27. Tenover F.C., Arbeit R.D., Goering R.V., Mickelsen P.A., Murray B.E., and Persing D.H. Swaminathan. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 33 (1995) 2233-2239
28. Giwercman B., Lambert P.A., Rosdahl V.T., Shand G.H., and Høiby N. Rapid emergence of resistance in Pseudomonas aeruginosa in cystic fibrosis patients due to in-vivo selection of stable partially derepressed β-lactamase producing strains. J Antimicrob Chemother 26 (1990) 247-259
29. Høiby. Microbiology of the lung infections in cystic fibrosis patients. Acta Paediatr Scand suppl 301 (1982) 33-54
30. Koch C., Frederiksen B., and Høiby N. Patient cohorting and infection control. Semin Respir Crit Care Med 6 (2003) 703-716
31. Høiby N., and Pedersen S.S. Estimated risk of cross-infection with Pseudomonas aeruginosa in Danish cystic fibrosis patients. Acta Paediatr Scand 78 (1989) 395-404
32. Jelsbak L., Johansen H.K., Frost A.L., Thøgersen R., Thomsen L.E., Ciofu O., Yang L., Haagensen J., Høiby N., and Molin S. Molecular epidemiology and dynamics of Pseudomonas aeruginosa populations in cystic fibrosis lungs. Infect. Immun 75 (2007) 2214-2224
33. Haagensen J.A., Klausen M., Ernst R.K., Miller S.I., Folkesson A., Tolker-Nielsen T., and Molin S. Differentiation and distribution of colistin-and sodium dodecyl sulfate-tolerant cells in Pseudomonas aeruginosa biofilms. J Bacteriol 189 (2007) 28-37
34. Rice L.B., and Bonomo R.A. Genetic and Biochemical Mechanisms of Bacterial Resistance to Antimicrobial Agents (2005) 441-508 In Philadelphia
35. Lowbury E.J.L., and Jones R.J. Treatment and prophylaxis for Pseudomonas infections. In: Brown M.R.W. (Ed). Resistance of Pseudomonas aeruginosa (1975), Arrowsmith ltd., Bristol 237-261
36. Substrathåndbogen, Statens Serum Institut, Copenhagen, Denmark. www.ssi.dk.
37. Casillas E., Kenny M.A., Minshew B.H., and Schoenknecht F.D. Effect of ionized calcium and soluble magnesium on the predictability of the performance of Mueller-Hinton agar susceptibility testing of Pseudomonas aeruginosa with gentamicin. Antimicrob Agents Chemother 19 (1981) 987-992
38. Hoffmann N., Rasmussen T.B., Jensen P.Ø., Stub C., Hentzer M., Molin S., Ciofu O., Givskov M., Johansen H.K., and Høiby N. A novel mouse model of chronic Pseudomonas aeruginosa lung infection mimicking cystic fibrosis. Infect Immun 73 (2005) 2504-2514
39. Ciofu O., Fussing V., Bagge N., Koch C., and Høiby N. Characterization of pair mucoid/non-mucoid Pseudomonas aeruginosa isolated from Danish cystic fibrosis patients: antibiotic resistance, beta-lactamase activity and RiboPrinting. J Antimicrob Chemother 3 (2001) 391-396
40. Ciofu O., Riis B., Pressler T., and Poulsen HE Høiby N. Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation. Antimicrob Agents Chemother 6 (2005) 2276-2282
41. Gacesa P., and Russell N.J. In: Gacesa P., and Russell N.J. (Eds). Pseudomonas infection and alginates. Biochemistry, genetics and pathology (1990), Chapman and Hall, London 1-233
42. Pedersen S.S., Høiby N., Espersen F., and Koch C. Role of alginate in infection with mucoid Pseudomonas aeruginosa in cystic fibrosis. Thorax 47 (1992) 6-13
43. Hansen C.R., Pressler T., Koch C., and Høiby N. Long-term Azithromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study. J Cyst Fibros 4 (2005) 35-40
44. Hodson M.E., Gallagher C.G., and Govan J.R.W. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J 20 (2002) 658-664